| Gene symbol | MS4A1 | Synonyms | B1, Bp35, CD20, CVID5, FMC7, LEU-16, S7 | Type of gene | protein-coding |
| Chromosome | 11 | Map location | 11q12.2 | dbXrefs | |
| Description | membrane spanning 4-domains A1 | ||||
| GTO ID | GTC1498 |
| Trial ID | NCT02290951 |
| Disease | Diffuse Large B-Cell Lymphoma | Follicular Lymphoma |
| Altered gene | CD20 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | Odronextamab |
| Phase | Phase1 |
| Recruitment status | Active, Not Recruiting |
| Title | Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies |
| Year | 2014 |
| Country | United States |
| Company sponsor | Regeneron Pharmaceuticals |
| Other ID(s) | R1979-HM-1333|2015-004491-30 |
| Cohort1: DLBL_Intravenous infusion | |||||||||
|
|||||||||
| Cohort2: FL_Subcutaneous injection | |||||||||
|
|||||||||
| Cohort3: DLBL_Subcutaneous injection | |||||||||
|
|||||||||